between lipid profile and CVD. In that study, CVD risk was 1.7 fold higher in patients with TC >230 mg/dL compared to patients with TC <160 mg/dL. The CVD risk was also associated with elevated LDL-C, triglycerides (TG), and low levels of high density lipoprotein cholesterol (HDL-C) ( Fig. 1 ).
CARDIOVASCULAR RISK ESTIMATION
All current guidelines on the prevention of CVD in clinical practice recommend the assessment of total CVD or CV risk, because in most people atherosclerotic CVD is the product of a number of risk factors. Many risk assessment Optional LDL-C goal <100 mg/dL. # Any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglyceride, low HDL-C, or metabolic syndrome) is a candidate for therapeutic lifestyle changes to modify these risk factors regardless of LDL-C level. **When LDL-lowering drug therapy is employed, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. † † If baseline LDL-C is <100 mg/dL, institution of an LDL-lowering drug is a therapeutic option on the basis of available clinical trial results. If a high-risk person has high triglycerides or low HDL-C, combining a fibrate or nicotinic acid with an LDL-lowering drug can be considered. ‡ ‡ For moderately high-risk persons, when LDL-C level is 100 to 129 mg/dL, at baseline or on lifestyle therapy, initiation of an LDL-lowering drug to achieve an LDL-C level <100 mg/dL is a therapeutic option on the basis of available clinical trial results.
systems are available, and most guidelines use risk estimation systems based on either the Framingham or SCORE (Systemic Coronary Risk Estimation) projects.
However, these systems are targeted towards Caucasians, and the validity of these risk estimation tools in Asian populations that have different lifestyles, social environments, and genetic backgrounds is less clear.
A Korean cancer prevention study (KCPS) developed a CVD and CV risk assessment model, which was crafted from data for over 1. Fig. 1 ). www.lipid.or.kr Table 2 .
GUIDELINES OF OTHER COUNTRIES

Guidelines in Japan
The first consensus for treating hyperlipidemia was with Japanese population (Table 3 ). Since the prevalence of CVD in Japan was lower but that of atherosclerotic CV was two-fold higher when compared with western populations, the risk estimation model was designed to more greatly emphasize the importance of controlling LDL-C in preventing atherosclerotic CV.
DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIA IN KOREA
Diagnostic criteria
Screening is essential for monitoring dyslipidemia because dyslipidemia usually accompanies no specific symptoms. It is recommended that screening should begin at the age of 20 and continue at least once every five years. The diagnostic criteria of dyslipidemia is shown in Table 4 .
Treatment targets
Treatment targets for dyslipidemia are primarily based on results from many clinical trials. However, there are few large RCTs that included Korean patients. In nearly Limit calorie intake from fat (less than 20-25% of total calorie intake), especially saturated fatty acids High monounsaturated fat diet, which is known to decrease CVD risk and LDL-C level.
High polyunsaturated fatty acids (ω-3 and ω-6) diet.
In the case of ω-3 fatty acids, 2-4 g/day is the recommended dose.
High dietary fiber intake. ATP III recommends 5-10 g/day, but 10-25 g/day may be more beneficial.
Replace saturated fatty acids with carbohydrate foods rich in fibers. Carbohydrates are recommended to comprise less than 60% of total calorie intake.
Limit alcohol intake (up to 1-2 drinks/day, corresponding to 10-30 g/day of alcohol).
Exercise
Physical activity is another important component of , Table   12 ) 
HMG CoA reductase inhibitors (Statins
HMG
Fibrates (Table 13)
Fibric acid derivatives are agonists of peroxisome proliferator-activated receptor (PPAR) α, a nuclear receptor involved in the regulation of lipid metabolism.
Fibrates stimulate lipoprotein lipase (LPL) activity (enhan- 
Nicotinic acids (niacin, Table 14)
Nicotinic acid, or niacin, is a B-complex vitamin, and is the only currently available lipid-lowering drug that significantly reduces plasma levels of lipoprotein A (Lp(a) ).
Nicotinic acid has been reported to decrease fatty acid influx to the liver and the secretion of VLDL by the liver.
It also suppresses transport of cholesterol from HDL to VLDL.
Nicotinic acid is most effective drug for increasing HDL-C. In addition, it reduces effectively not only TG levels but also LDL-C, reflecting its effect on all apo B-containing proteins. It is also the only currently available lipid-lowering www.lipid.or.kr 
Ezetimibe
DRUG COMBINATIONS
Although target levels of LDL-C can be reached with monotherapy in many patients, a proportion of high risk patients with very high LDL-C levels need additional treatment. There are also patients who are statin intolerant or are subsequently not able to tolerate higher doses.
In these cases combination therapy should be considered.
Statin + Fibrate
Clinical trials have shown that the combination of a statin and a fibrate results in a significantly stronger reduction in LDL-C and TG as well as a greater elevation of HDL-C in comparison to monotherapy. Since gemfibrozil is the drug most associated with myopathy, avoid that drug when combination therapy is needed.
Statin + Niacin
The combination of nicotinic acid with moderate doses of a statin provides a significantly better increase in HDL-C and decrease in TG in comparison to a high dose of a statin monotherapy. In clinical trials, this combination therapy showed a decreased risk of CVD and atherosclerosis, and the incidence of flushing was similar in patients with and without statin treatment.
Statin + Omega-3 fatty acids
Treatment with a combination of 4 g/day n-3 fatty acids and simvastatin caused a stronger reduction of TG concentration when compared with statin use alone. This combination may decrease small-dense LDL and improve the postprandial rise of TG.
MANAGEMENT OF DYSLIPIDEMIA OF SPECIAL CLINICAL SETTINGS
Diabetes mellitus
Management targets [A]
▪ LDL-C <100 mg/dL (70 mg/dL for those who have 
The elderly
The proportion of elderly people in society is increasing, www.lipid.or.kr Table 17 . Older adults often have co-morbidities, use multiple medications, and have altered pharmacokinetics and pharmacodynamics. Therefore, the safety and side effect profile of statins should be strongly considered, and lipid profile, liver enzymes and kidney function should be checked regularly. Since older individuals are less likely to receive lipid-lowering medications and but with poor adherance to statin therapy, understanding of CV risk, the medication regimen and potential benefits of persistence is necessary to enhance their compliance to statin therapy.
